Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Receivables - Net (2020 - 2025)

Historic Receivables - Net for BioNexus Gene Lab (BGLC) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • BioNexus Gene Lab's Receivables - Net rose 679.24% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 679.24%. This contributed to the annual value of $1.4 million for FY2024, which is 7214.15% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Receivables - Net is $1.5 million, which was up 679.24% from $1.9 million recorded in Q2 2025.
  • BioNexus Gene Lab's Receivables - Net's 5-year high stood at $4.2 million during Q3 2021, with a 5-year trough of $799674.0 in Q4 2023.
  • For the 5-year period, BioNexus Gene Lab's Receivables - Net averaged around $2.2 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, BioNexus Gene Lab's Receivables - Net plummeted by 7212.09% in 2023, and later surged by 8746.52% in 2025.
  • Over the past 5 years, BioNexus Gene Lab's Receivables - Net (Quarter) stood at $3.4 million in 2021, then dropped by 14.55% to $2.9 million in 2022, then crashed by 72.12% to $799674.0 in 2023, then skyrocketed by 72.14% to $1.4 million in 2024, then increased by 10.58% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.9 million for Q2 2025, and $1.4 million during Q1 2025.